Letter to the Editor

Response to Paterson et al.

  • The American Journal of Gastroenterology (2017) 112, 18891892 (2017)
  • doi:10.1038/ajg.2017.373
  • Download Citation
Published online:
  • Subscribe to The American Journal of Gastroenterology for full access:

    $870

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , et al. Breath testing consensus guidelines for SIBO: RES IPSA LOCQUITOR. Am J Gastroenterol 2017 (this issue).

  2. 2.

    , , et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the north american consensus. Am J Gastroenterol 2017;112:775–784.

  3. 3.

    , , et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013;145:1262–70 e1.

  4. 4.

    , , et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci 2013;58:2594–2598.

  5. 5.

    , , et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157–1160.

  6. 6.

    , , et al. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. Middle East J Dig Dis 2015;7:36–40.

  7. 7.

    , , et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008;6:759–764.

  8. 8.

    , , et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008;103:1257–1262.

  9. 9.

    , , et al. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol 2006;25:6–10.

  10. 10.

    , , et al. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case-control study. Can J Gastroenterol Hepatol 2016;2016:7424831.

  11. 11.

    , , et al. Etiopathogenesis of rosacea: a prospective study with a three-year follow-up. G Ital Dermatol Venereol 2017;152:418–423.

  12. 12.

    , , et al. The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome. Gut Liver 2009;3:174–179.

  13. 13.

    , , et al. Small intestine bacterial overgrowth in patients with chronic pancreatitis. Rev Med Chil 2008;136:976–980.

  14. 14.

    , , et al. Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients. Rev Gastroenterol Mex 2015;80:171–174.

  15. 15.

    , , et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241–1249.

  16. 16.

    , , et al. Breath hydrogen and methane are associated with intestinal symptoms in patients with chronic pancreatitis. Pancreatology 2015;15:514–518.

  17. 17.

    , , et al. Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath test. J Korean Med Sci 2013;28:901–907.

  18. 18.

    , . Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005;100:1566–1570.

  19. 19.

    , , et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil 2014;26:794–802.

  20. 20.

    , , et al. Lactulose breath test results in patients with persistent abdominal symptoms following Giardia lamblia infection. Scand J Gastroenterol 2008;43:141–145.

  21. 21.

    , , et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007;56:802–808.

  22. 22.

    , , . Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008;103:958–963.

Download references

Author information

Affiliations

  1. GI Motility Program, Division of Gastroenterology, Department of Medicine, Cedars-Sinai, Los Angeles, California, USA

    • Ali Rezaie
  2. Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

    • Michelle Buresi
  3. Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia, USA

    • Satish Rao

Authors

  1. Search for Ali Rezaie in:

  2. Search for Michelle Buresi in:

  3. Search for Satish Rao in:

Competing interests

Ali Rezaie reports support from the following sources for consultation: Commonwealth Laboratories, Actavis, Salix Pharmaceuticals and Synergy Pharmaceuticals. Michelle Buresi reports no conflicts of interest. Satish Rao reports support from the following sources for teaching, research, and consultation, outside the submitted work: Forest Laboratories, Hollister, Ironwood Pharmaceuticals, Sucampo Pharmaceuticals, In Control Medical, Vibrant, American Medical Systems, Sun Sweet Corporation, Synergy Pharmaceuticals, Salix Pharmaceuticals, and Ventrus Laboratories.

Corresponding author

Correspondence to Ali Rezaie.